In this study, 2 out of 40 mice (one each from Her2-CAR T cells treatment group and Her2CAR-cFLIPp43 CAR T cells treatment group) developed GvHD-like symptoms after day 40 post-tumour-challenge. This evidence concerns the gene ERBB2 and neoplasm.